KADAR ANTIBODI IgG SARS COV-2 SETELAH VAKSINASI COVID-19 DOSIS LANJUTAN
Main Article Content
Abstract
COVID-19 is a problem throughout the world, including Indonesia. One of the efforts to overcome the COVID-19 pandemic is vaccination. A follow-up or booster dose was needed to increase individual protection because there was a decrease in antibodies 6 months after receiving vaccination. This study aimed to determine SARS-CoV-2 IgG antibody levels before and after 8 months of the third booster vaccination. This research method was observational with a longitudinal, cohort approach to 27 samples using a consecutive sampling technique at the Health Polytechnic of the Ministry of Health, Jakarta III in April-November 2022. The data collection techniques used questionnaires and venous blood sampling to examine quantitative Anti-SARS CoV-2 Ig G levels using the CMIA (Chemiluminescent microparticle immunoassay) method with the Architect tool which was carried out twice, namely before administration and 8 months after the third booster vaccination with a heterologous vaccine. Data were analyzed using a statistical test of the difference between the means of two groups. Based on the research results, although statistically there was no significant difference between before and 8 months after vaccination (p=0.055), there was a decrease in the mean quantitative Anti-SARS CoV-2 IgG level of 5301.24 AU/mL. As many as 63% of subjects experienced a decrease in antibody levels 8 months after vaccination compared to before the third booster vaccination. Longitudinal studies are needed to determine protective antibody levels.
Article Details
References
WHO, “Coronavirus disease (COVID-19) pandemic,” 2020.
Kemenkes RI, Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19) Revisi ke-5. Jakarta: Kementerian Kesehatan RI, 2020.
Satgas Penanganan COVID-19, “Peta Sebaran COVID-19 DKI Jakarta,” 2021.
S. Kashte, A. Gulbake, S. F. El-Amin III, and A. Gupta, “COVID-19 vaccines: rapid development, implications, challenges and future prospects,” Hum. Cell, vol. 34, no. 3, pp. 711–733, 2021.
S. Kumar, R. Nyodu, V. K. Maurya, and S. K. Saxena, “Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),” in Coronavirus Disease 2019 (COVID-19), Springer, 2020, pp. 23–31.
S. Xiu et al., “Inhibitors of SARS-CoV-2 entry: current and future opportunities,” J. Med. Chem., vol. 63, no. 21, pp. 12256–12274, 2020.
Kementerian Kesehatan RI, “Vaksinasi COVID-19 Dosis Lanjutan (Booster).” Kementerian Kesehatan RI, 2022.
Kementerian Kesehatan RI, “Penambahan Regimen Vaksinasi COVID-19 Dosis Lanjutan (Booster).” Kementerian Kesehatan RI, Jakarta, 2022.
N. Ghiasi et al., “Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion,” Immunopathol. Persa, vol. 7, no. 2, pp. e31–e31, 2021.
K. S. Corbett et al., “SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness,” Nature, vol. 586, no. 7830, pp. 567–571, 2020.
F. P. Polack et al., “Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine,” N. Engl. J. Med., vol. 383, no. 27, pp. 2603–2615, 2020.
E. J. Valcourt et al., “Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2),” Diagn. Microbiol. Infect. Dis., vol. 99, no. 4, p. 115294, 2021.
G. A. Poland, I. G. Ovsyannikova, and R. B. Kennedy, “SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates,” Lancet, vol. 396, no. 10262, pp. 1595–1606, 2020.
Kusmardi, R. N. Dimas, P. Pratomo Irandi, and T. Aryo, “Peran sel T memori dalam pengendalian pandemi COVID-19,” Maj. Patol. Indones., vol. 30, no. 2, 2021.
M. H. G. Fonseca, T. de F. G. de Souza, F. M. de Carvalho Araújo, and L. O. M. de Andrade, “Dynamics of antibody response to CoronaVac vaccine,” J. Med. Virol., vol. 94, no. 5, pp. 2139–2148, 2022.
R. Fajrunni’mah, A. Purwanti, F. Khasanah, and B. Setiawan, “Status Kadar Antibodi Spike Receptor Binding Domain setelah Vaksinasi Kedua menggunakan Vaksin Inaktivasi,” Heal. Inf. J. Penelit., vol. 14, no. 2, pp. 142–152, 2022. doi: 10.36990/hijp.v14i2.636
G. Lippi, G. L. Salvagno, B. M. Henry, L. Pighi, S. De Nitto, and G. Gianfilippi, “Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination,” Adv. Lab. Med., vol. 3, no. 1, pp. 39–43, 2022.
M. Skorupa et al., “The Dynamics of Changes in the Concentration of IgG against the S1 Subunit in Polish Healthcare Workers in the Period from 1 to 12 Months after Injection, Including Four COVID-19 Vaccines,” Vaccines, vol. 10, no. 4, pp. 1–22, 2022.
M. R. Faas et al., “Dynamics of Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and the Impact of Booster Vaccinations in Previously Infected and Infection-Naïve Individuals,” Vaccines, vol. 10, no. 2132, pp. 1–15, 2022.
M. E. Romero-Ibarguengoitia et al., “Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare personnel,” PLoS One, vol. 17, no. 3 March, pp. 1–13, 2022.
R. Yorsaeng et al., “Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults,” Vaccine, vol. 40, no. 3, pp. 524–530, 2022.
M. Belik et al., “Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants,” Nat. Commun., vol. 13, no. 1, pp. 1–10, 2022.
B. Doroftei, A. Ciobica, O. D. Ilie, R. Maftei, and C. Ilea, “Mini-review discussing the reliability and efficiency of covid-19 vaccines,” Diagnostics, vol. 11, no. 4, pp. 1–11, 2021.
Z. Business, “Coronavirus Vaccine Covishield: Side effects, Benefits of Serum Institute-AstraZeneca vaccination.” Zee Business, 2021.
J. Pailliez and J. Ahlander, “AstraZeneca vaccine faces resistance in Europe after health workers suffer side-effects. Reuters; February 18, 2021.” .